ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Alendronate

Also written as “alendronate”, “Comparator: alendronate” and “Liposomal Alendronate”.

Its studies are mostly in Osteoporosis, Postmenopausal · Osteoporosis · Osteitis Deformans · Coronary Stenosis · Back Pain, led by 8 companies.

Drug pageAlendronate: every studyMany companies study it; this page follows only the 17 they lead. All 91 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 5, 200817 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organon90 open or runningphase 4since Aug 5, 2008Sep 21, 2004none ahead
Viatrisits history only20 open or runningphase 1since Sep 21, 2009Sep 21, 2009none ahead
BIOrestits history only10 open or runningphase 2since Aug 20, 2008Aug 20, 2008none ahead
Dr. Reddy's Laboratoriesits history only10 open or runningphase 1since May 27, 2010May 27, 2010none ahead
Evangelisches Krankenhaus Lutherhaus gGmbHits history only10 open or runningphase 3since Jan 11, 2012Jan 11, 2012none ahead
GlaxoSmithKlineits history only10 open or runningphase 4since May 18, 2006May 18, 2006none ahead
Radius Healthits history only10 open or runningphase 3since Jul 31, 2012Jul 31, 2012none ahead
Teva Pharmaceutical Industriesits history only10 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Organon only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 21, 2004First studies: 3 phase 3 studies in Osteoporosis, PostmenopausalFirst studyNCT00092040, NCT00092027, NCT00092014
  2. Nov 10, 2006Phase 3 study in Osteoporosis, PostmenopausalNCT00398931 · 1,099 enrolled
  3. May 30, 20072 phase 3 studiesNCT00480766, NCT00480662
  4. Aug 5, 2008Phase 4 study in Osteoporosis, PostmenopausalNCT00729651 · 343 enrolled
  5. Dec 4, 20082 phase 1 studies in OsteoporosisNCT00803790, NCT00806416

TargetBeta

FDPS →read by rule
“Farnesyl diphosphate synthase inhibitor”ChEMBL 37, by rule

Studies

All 9 Organon leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00806416Osteoporosis1CompletedAug 2003244
NCT00803790Osteoporosis1CompletedJul 2006318
NCT00729651Osteoporosis, Postmenopausal4CompletedApr 10, 2009343
NCT00480766Osteoporosis3CompletedAug 2003173
NCT00480662Osteitis Deformans3CompletedOct 200260
NCT00398931Osteoporosis, Postmenopausal3CompletedOct 20031,099
NCT00092040Osteoporosis, Postmenopausal3CompletedOct 18, 2004936
NCT00092027Osteoporosis, Postmenopausal3CompletedMar 15, 2004454
NCT00092014Osteoporosis, Postmenopausal3CompletedApr 1, 20041,053

How it is read

Names in the registry

  • “Alendronate”, 7 entries
  • “alendronate”, 2 entries
  • “Comparator: alendronate”, 2 entries
  • “Liposomal Alendronate”, 2 entries
  • “Alendronate Sodium Tablets, 70 mg”, 2 entries

Codes read as this program: MK0217.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.